Amyloid b-peptide (Ab) cytotoxicity, the hallmark of Alzheimer's disease, implicates oxidative stress in both neurons and vascular cells, particularly endothelial cells. Consequently, antioxidants have shown neuroprotective activities against Ab-induced cytotoxicity. Among the different antioxidants used in both in vitro and in vivo studies, 17b-oestradiol (E 2 ) has garnered the most attention. Oestrogen attenuated Ab E22Q -induced toxicity in neurons but failed to protect endothelial cells. Here we show that E 2 -mediated activation of endothelial nitric oxide synthase (eNOS) increases the production of nitric oxide (NO), which, under Ab E22Q -induced oxidative damage, results in the formation of peroxynitrite and increased nitration of tyrosine residues. Inhibition of eNOS prevents nitrotyrosination and permits E 2 -mediated protection against Ab E22Q on endothelial cells. The main nitrotyrosinated proteins in the presence of E 2 and Ab E22Q were identified by MALDI-TOF mass spectrometry. These proteins are key players in the regulation of energy production, cytoskeletal integrity, protein metabolism and protection against oxidative stress. Our data highlight the potential damaging consequences of E 2 in vascular disorders dealing with oxidative stress conditions, such as cerebral amyloid angiopathy, stroke and ischaemia-reperfusion conditions. Keywords: Alzheimer's disease; amyloid b-peptide; oestrogen; nitric oxide; nitrotyrosination Abbreviations: Ab = amyloid b-peptide; E 2 = 17b-oestradiol; ECs = endothelial cells; eNOS = endothelial nitric oxide synthase; HA-VSMCs = human aortic vascular smooth muscle cells; HUVECs = human umbilical vein endothelial cells; L-NNA = N G -nitro-L-arginine; NO = nitric oxide; NOS = NO synthase; PTIO = 4,5,5-tetramethylimidazoline-1-oxyl 3-oxide
Introduction
The vascular pathology associated to Alzheimer's disease resulting in the presence of amyloid b-peptide (Ab) fibrils in brain vessels is denominated cerebral amyloid angiopathy (CAA) (Ghiso and Frangione, 2001) . The hereditary cerebral haemorrhage with amyloidosis of the Dutch type (HCHWA-D) is a familiar kind of CAA. HCHWA-D patients show diffuse amyloid deposits in the brain parenchyma and mature deposits in the brain vasculature, which degenerates, producing haemorrhages (Ghiso and Frangione, 2001) . HCHWA-D is produced by a mutation in the Ab-encoding gene, which causes the replacement of Glu!Gln at position 22 (Ab E22Q ), eliciting a more fibrillogenic Ab than the wildtype (Muñoz et al., 2002) . This mutated Ab has been also demonstrated to be more toxic than the Ab wild-type (Muñoz et al., 2002) .
The cell damage induced by Ab involves oxidative stress (Butterfield and Bush, 2004) . Thus post mortem studies showed oxidative markers in lipids, proteins and nucleic acids from Alzheimer's disease patients (Miranda et al., 2000) . Moreover, in vitro studies have demonstrated the involvement of oxidative stress in Ab-mediated cytotoxicity in neuronal (Behl, 1997) and vascular cells (Muñoz et al., 2002) . Endothelial dysfunction induced by Ab can be increased by the formation of the powerful nitrating agent peroxynitrite (ONOO -), resulting from the reaction of nitric oxide (NO) with superoxide (O 2 the consequences of large amounts of peroxynitrite is protein nitrotyrosination, which compromises cellular function and viability (Radi, 2004) . Interestingly, massive peroxynitration has been reported in brains from Alzheimer's disease patients (Castegna et al., 2003) .
Owing to the involvement of oxidative stress in the pathophysiology of Alzheimer's disease, many therapeutic approaches based on the use of antioxidants have been tested (Miranda et al., 2000) . Vitamin E and other antioxidants protect against Ab-cytotoxicity in neuronal (Butterfield et al., 1999) and vascular (Miranda et al., 2000) cells. The sex hormone 17b-oestradiol (E 2 ) also protects against Ab challenge in neurons (Bonnefont et al., 1998) , but fails to protect endothelial cells challenged with Ab or H 2 O 2 (Muñoz et al., 2002) . E 2 might have many roles in neuroprotection (Behl, 2002) , including its neurotrophic (Garcia-Segura et al., 2001) and antioxidant (Moosmann and Behl, 1999) properties. E 2 also presents pleiotropic beneficial effects on the vasculature (Mendelsohn, 2002b) , particularly favouring vasodilatation by increasing NO bioavailability . However, this effect might become deleterious under conditions of increased oxidative stress, when NO production by E 2 stimulation could result in excessive peroxynitrite formation.
In the present work we studied the effect of E 2 on Ab E22Q -mediated cytotoxicity in human aortic vascular smooth muscle cells (HA-VSMCs) and human umbilical vein endothelial cells (HUVECs) , and primary cultures of mouse cortical neurons and glial cells. We used 10 mM E 2 because the concentration of E 2 acting as an antioxidant in vitro is in the micromolar range (Behl, 2002) , which is far from the physiological circulating levels but close to the E 2 concentration in microenvironments of the cell membranes where it can be massively inserted. Cell viability, the presence of apoptotic markers and identification of nitrotyrosinated proteins were also assayed in HUVECs challenged with Ab E22Q and treated with E 2 in the presence of the NO synthase (NOS) inhibitor N G -nitro-L-arginine (L-NNA) or with the NO scavenger 4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO), which reacts with NO stoichiometrically and avoids its bioavailability without affecting NOS activity (Akaike et al., 1993) .
Material and methods Materials
Synthetic Ab peptide corresponding to the human Ab 1-40 Dutch variant that contains a glutamic acid to glutamine substitution (Ab E22Q ) was purchased from Oncogene (Darmstadt, Germany). Ab E22Q produces more stable fibrils than Ab wild-type, but there are no differences in the amyloidogenic properties between the two Ab types (Muñoz et al., 2002) . Amyloid fibrils were obtained and characterized as described previously (Muñoz et al., 2002) . Ab E22Q fibrils were used at a final concentration of 0.125 mM on HUVECs, 0.25 mM on HA-VSMCs, and 1.25 mM on neuronal and glial cells in order to obtain a viability of $60%. All media and culture products were purchased from Gibco-BRL (Paisley, UK). Experiments were performed with phenol red-and serum-free media. All chemicals were obtained from Sigma (St Louis, MO, USA) unless otherwise indicated.
Cell cultures
HUVECs were grown in M-199 medium supplemented with 10% fetal bovine serum (FBS), 3.2 mM glutamine and antibiotics (100 U/ml penicillin and 10 -6 mg/ml streptomycin). Mouse lung capillary endothelial cells (1G11 ECs) (kindly provided by Dr. A. Mantovani; Dong et al., 1997) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% FBS, 150 mg/ml of endothelial cell growth supplement (Becton-Dickinson, Bedford, MA, USA), 100 mg/ml of heparin, 1% non-essential amino acids and antibiotics. Porcine aortic endothelial cells (PAECs) were grown in DMEM supplemented with 10% FBS and antibiotics. Murine haemangioma endothelial cells (Py-4-1 ECs) were grown in DMEM supplemented with 10% FBS, 2 ng/ml of basic fibroblast growth factor (bFGF) and antibiotics. HA-VSMCs (kindly provided by Dr. S. Richard) were grown in RPMI MCDB 131 medium supplemented with 5% FBS, 5 · 10 À7 g/l EGF, 1.5 · 10 À6 g/l bFGF, 5 g/l insulin, 2 mM L-glutamine and antibiotics. Mouse cortical neurons were isolated from 18-day-old OS-1 mouse embryos and cultured in DMEM plus B27 (Gibco-BRL) on poly-L-lysine-coated plates. Glial cultures were obtained from 2-day-old mice and cultured in DMEM plus 10% FBS. Cortical neurons were used after 6 days in culture and glial cells after the second passage. Animals were manipulated according to the Council of the European Union (86/6091 EU) and to the ethics committee of the Institut Municipal d'Investigació Mèdica-Universitat Pompeu Fabra (IMIM-UPF).
Brain samples
Brain tissue sections were supplied by the Banc de Teixits Neurolò gics (Serveis Científico-Tècnics, Hospital Clínic, Universitat de Barcelona). The procedure was approved by the ethics committee of the IMIM-UPF. Brain sections (5 mm) were obtained from the frontal cortex of three control males, seven control females, six males with Alzheimer's disease (stage VI) and six females with Alzheimer's disease (stage VI), none receiving hormone replacement therapy.
Cell viability assay
Cells were seeded in 96-well plates at a density of 8000 cells/100 ml (HUVECs and HA-VSMCs) or 20 000 cells/100 ml (cortical neurons and glial cells) per well. Cells were challenged with Ab E22Q , 10 mM H 2 O 2 or PBS. E 2 (0.1 mM or 10 mM) was added 1 h before Ab E22Q fibrils or H 2 O 2 . L-NNA (100 mM) or PTIO (10 mM) was added 1 h before E 2 treatment. Trolox (a water-soluble analogue of vitamin E that maintains the OH in the mesomeric ring where the free radical scavenger activity is located and lack of the hydrophobic aliphatic chain of vitamin E; McClain et al., 1995) was used at 100 mM. 17a-oestradiol was used at 1 mM. Oestrogen receptor (ER) antagonists (0.1 mM) ICI 182,780 (a 7a-alkylamide analogue of estradiol with pure anti-oestrogenic activity) or tamoxifen (a non-steroidal triphenylethylene derivative acting as a partial ER antagonist) was added 1 h before E 2 . Cells were incubated for 24 h at 37 C and cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction method. Assays were run in triplicate, determined in a Microplate Reader (Model 550; Bio-Rad, Hercules, CA, USA) and data expressed as percentage of control.
Apoptosis assay
HUVECs (4 · 10 4 ) were seeded on 1% poly-L-lysine-coated coverslips and treated for 6 h at 37 C with Ab E22Q , E 2 and L-NNA or PTIO. Coverslips were processed with the DeadEnd TM Colorimetric TUNEL System (Promega, Madison, WI, USA). Representative digital images were taken with a Leica DMRB and analysed with CCD Leica DC300F (Heidelberg, Germany).
Akt phosphorylation
HUVECs (1.5 · 10 6 ) were seeded on 90-mm plates and treated for 24 h at 37 C with Ab E22Q or E 2 . Cells were lysed and 75 mg protein per sample was run in 10% SDS-PAGE. Blotted nitrocellulose membranes were incubated with 1 : 500 mouse anti-phospho-Akt (Ser473) monoclonal antibody (Ab) (Cell Signaling, Beverly, MA, USA) overnight at 4 C or rabbit anti-b-actin monoclonal Ab for 1 h at room temperature as loading control. It was followed by incubation with 1 : 5000 sheep anti-mouse peroxidase-conjugated polyclonal Ab or donkey anti-rabbit peroxidase-conjugated polyclonal Ab (Amersham Bioscience, Barcelona, Spain) for 1 h at room temperature. Bands were visualized using the enhancer chemiluminescence substrate Super Signal (Pierce, Rockford, IL, USA) and Amersham Bioscience Hyperfilm ECL kit.
Nitrotyrosine immunoreactivity on endothelial cells
HUVECs, PAECs, 1G11 ECs and Py-4-1 ECs (4 · 10 4 ) were seeded on 1% poly-L-lysine coated coverslips and treated for 24 h at 37 C with Ab E22Q , E 2 , sodium nitroprussiate (SNP) and L-NNA or PTIO. Cells were fixed and incubated for 2 h at room temperature with 1 : 500 rabbit anti-nitrotyrosine polyclonal Ab (Molecular Probes, Leiden, The Netherlands) followed by incubation with 1 : 500 Alexa Fluor 488 goat anti-rabbit polyclonal Ab for 1 h at room temperature. Digital images were taken with a Leica TCS SP confocal microscope and analysed with Leica confocal software (Heidelberg, Germany).
Brain sample staining
Sections were treated with alkaline solution followed by Congo Red staining. The following sections were treated with 4% H 2 O 2 and incubated with 1 : 500 rabbit anti-nitrotyrosine polyclonal Ab for 2 h at room temperature followed by incubation with 1 : 5000 biotinilated goat anti-rabbit polyclonal Ab (DAKO, Glostrup, Denmark) for 1 h at room temperature. Slides were incubated with streptavidin-horseradish peroxidase (Zymed Laboratories, San Francisco, CA, USA) and treated with Peroxidase Substrate Kit DAB (Vector, Burlingame, CA, USA). Samples were counterstained with haematoxylin, dehydrated and fixed with Eukitt (O. Kindler, GmbH., Fribourg, Switzerland). Representative digital images were taken and analysed as described above.
NO assay
HUVECs (1.5 · 10 6 ) seeded on 90-mm plates were treated with Ab E22Q , E 2 and L-NNA or PTIO for 24 h. Cells were lysed and protein concentration determined by the Bio-Rad protein assay. NO was measured (40 ml samples in triplicate) using a nitrate/nitrite colorimetric assay kit (Cayman, Ann Arbor, MI, USA). NO production was calculated to the amount of protein.
Identification of nitrotyrosinated proteins
HUVECs (1.5 · 10 6 ) were seeded on 90-mm plates and treated for 24 h at 37 C with Ab E22Q , E 2 and L-NNA or PTIO. Cells were lysed in 100 ml buffer (7 M urea, 2 M thiourea, 4% CHAPS, 2% IPG buffer 3-10 NL, 1% DTT and protease inhibitors), sonicated, acetone precipitated and subsequently centrifuged.
2D gel electrophoresis
Protein (200 mg) was dissolved up to 125 ml buffer (7 M urea, 2 M thiourea, 4% CHAPS, 0.5% IPG buffer 3-10 NL and 1.2 ml Destreak reagent). Isolectric focusing was carried out at 20 C. The rehydration step was carried out for 12 h at 50 V, and was followed by 1 h at 200 V, 30 min at 500 V, 30 min at 1000 V, a 40 min gradient until 5000 V, and 4 h at 5000 V. Gel strips were equilibrated in DTT and iodoacetamide-based buffers and loaded onto 12% SDS-PAGE. Duplicate gels were run for each sample, one for western blot and another for protein identification.
Western blot
Nitrocellulose membranes were incubated for 2 h at room temperature with 1 : 500 rabbit anti-nitrotyrosine polyclonal Ab and for 1 h at room temperature with 1 : 5000 donkey anti-rabbit peroxidaseconjugated polyclonal Ab (Amersham Bioscience). Bands were visualized as described above. The protein identification was performed in gels stained with Coomassie R-350. Bands matching those shown to contain nitrotyrosine by western blot in the duplicate set (see above) were unstained by sequential hydration/dehydration steps with 0.1 M NH 4 HCO 3 (pH 8) and acetonitrile, respectively. Gel plugs were dried in a Speed-Vac for 5 min. Each spot was treated with 100 ng sequencing-grade trypsin in 50 mM NH 4 HCO 3 and incubated for 30 min at 4 C and then overnight at 37 C. Digested samples (10 ml) were desalted with a Poros R2 column (ABI). Peptide mass fingerprints were obtained in a Voyager DE-STR MALDI-TOF mass spectrometer (Applied Biosystems, Foster City, CA, USA) and searched against the NCBI and Swiss-Prot protein databases using the MAS-COT search engine. Peptide mass fingerprinting used the assumption that peptides were monoisotopic, oxidized at Met residues and carbamidomethylated at Cys residues. A mass tolerance of 50 ppm was the window error allowed for matching the peptide mass values.
Statistical analysis
Data are expressed as the mean ± SEM of the values from the number of experiments as indicated in the corresponding figures. Data were evaluated statistically using Student's t-test or one-way ANOVA, followed by Bonferroni's post hoc analysis. The level of significance was P < 0.05.
Results E 2 -mediated protection against Ab E22Q cytotoxicity in endothelial cells requires low NO bioavailability Ab E22Q fibrils from the Dutch variant induced marked cytotoxicity in vascular and neuronal cells (Fig. 1) . E 2 reverted the cytotoxic effect of Ab E22Q on cortical neurons and HAVSMCs (Fig. 1A) . However, it failed to revert Ab E22Q toxicity on HUVECs (Fig. 1B) . One possible explanation for the differential protective effect of E 2 is related to NO bioavailability.
Under physiological conditions NO is a powerful vasodilator but under oxidative conditions it becomes harmful to the cells due to peroxynitrite formation. E 2 is a well-known activator of endothelial nitric oxide synthase (eNOS) . Therefore, we evaluated the protective effect of E 2 against Ab E22Q in the presence of the NOS inhibitor L-NNA and the NO scavenger PTIO (Fig. 1B) . Under both conditions, E 2 significantly reduced the Ab E22Q -mediated cytotoxicity in HUVECs measured by MTT assay (P < 0.05). On the other hand, the presence of L-NNA or PTIO did not modify the cell viability of HA-VSMCs or cortical neurons (Fig. 1A) .
Interestingly, experiments carried out in mouse glial cells, which express the inducible isoform of NOS (iNOS), which is not regulated by E 2 (Fulton et al., 1999) , showed that E 2 increased cell viability (75 6 9%) in response to Ab E22Q (57 6 7%), and this protection was further increased (86 6 13%) in the presence of 100 mM aminoguanidine, a specific inhibitor of iNOS.
Ab E22Q toxicity, like oxidative stress in general, has been associated with the induction of apoptotic cell death (Muñoz et al., 2002) . Accordingly, the presence of apoptotic endothelial cells in response to Ab E22Q and the different treatments was tested using the TUNEL assay (Fig. 1C) . Under control conditions no apoptotic HUVECs were observed in a representative optical field. Treatment with Ab E22Q induced the appearance of numerous apoptotic cells that was not prevented by E 2 , but was reverted by coincubation with E 2 plus L-NNA or PTIO. Altogether, the results obtained using MTT and TUNEL assays indicate that the protective effect of E 2 against Ab E22Q is only achieved by inhibiting the eNOS or reducing the availability of NO with a NO scavenger. The same pattern of response was obtained when HUVECs were incubated with 10 mM H 2 O 2 , a pro-oxidant stimulus (Fig. 1D) . The most significant protection against Ab E22Q toxicity was provided by Trolox, a powerful antioxidant (Fig. 1E) .
ER-independent protection by E 2
Akt phosphorylation was observed in HUVECs exposed to E 2 (Fig. 2E) . Slight activation of Akt was also observed in cells treated with Ab E22Q . Since the PI3K/Akt pathway has been involved in the maintenance of cell survival (Franke et al., 2003) , this effect could be related to the triggering of protective mechanisms.
The role of ERa in the effect of E 2 in Ab E22Q -mediated cytotoxicity was assayed in HUVECs exposed to Ab E22Q or Ab E22Q plus E 2 in the presence of the ERa antagonists ICI 182,780 and tamoxifen ( Fig. 2A) . ER inhibition provides protection by E 2 against the Ab E22Q challenge in HUVECs (P < 0.05). Under these conditions, eNOS cannot be activated and the increased NO supply is prevented. On the other hand, the use of ER inhibitors did not modify the protective effect of E 2 on HA-VSMCs (Fig. 2B) . Since E 2 activates eNOS at physiological concentrations, E 2 was also assayed at 0.1 mM (Fig. 2C) , but protection was not obtained in the presence of L-NNA or PTIO. At this low concentration E 2 lacks its antioxidant ability. Accordingly, HUVECs challenged with Ab E22Q in the presence of 1 mM 17a-oestradiol (Fig. 2D) , which does not bind ER but maintains the antioxidant properties, were protected. Altogether, the data shown suggest that E 2 protection is independent of its binding to the ER.
Ab E22Q and Ab E22Q plus E 2 induce nitrotyrosination of protein residues that can be reverted by NO inhibitors Excessive NO production induced by E 2 -dependent activation of eNOS reduces the protective effect of E 2 in HUVECs Fig. 1 Effect of E 2 in Ab-mediated cytotoxicity. E 2 (10 mM) protected HA-VSMCs and cortical neurons (A) against 0.25 mM (for HA-VSMCs) and 1.25 mM (for neurons) Ab E22Q independently of 100 mM L-NNA and 10 mM PTIO. Data are mean 6 SEM values of three to seven experiments. HUVECs were challenged with 0.125 mM Ab E22Q fibrils (B) and protection with 10 mM E 2 was obtained only when NO inhibitors were present. Data are mean 6 SEM values of seven to nine experiments. HUVECs were treated and stained by TUNEL method detecting apoptotic cells (C). Pictures were taken from representative experiments (n = 3) performed in duplicate. HUVECs were challenged with 10 mM H 2 O 2 (D) in a representative experiment performed in triplicate and protection by E 2 was obtained solely in the presence of NO inhibitors. 100 mM Trolox protected Ab E22Q challenge on HUVECs (E). *P < 0.05. challenged with Ab E22Q . This finding could be related to the production of peroxynitrites in a pro-oxidant environment. Therefore, we studied protein nitrotyrosination in HUVECs (Fig. 3A, left panels) . We observed that in the absence of oxidative challenge HUVECs presented a low level of nitrotyrosination, determined by confocal immunofluorescence with an anti-nitrotyrosine Ab. Ab E22Q induced a significant increase in nitrotyrosination that further increased in the presence of E 2 and was reverted by L-NNA or PTIO. Identical results were obtained with other ECs: 1G11 ECs (Fig. 3B ), PAECs and Py-4-1 ECs (data not shown). Moreover, Ab E22Q challenged with a NO donor (sodium nitroprussiate) mimics the result obtained with Ab E22Q plus E 2 treatment on HUVECs (Fig. 3D) . The nitrotyrosination levels were transformed into a pseudocolour scale (Fig. 3A, right panels) and represented quantitatively as fluorescence arbitrary units (Fig. 3C ). Figure 3C also shows the NO levels as percentage relative to control conditions. Ab E22Q challenge, in addition to increasing nitrotyrosination of HUVECs, reduced the NO level, most likely owing to the formation of peroxynitrite following the reaction of NO with the superoxide anion generated by the presence of Ab E22Q . The highest levels of nitrotyrosination were observed in HUVECs exposed to Ab E22Q plus E 2 , in agreement with the highest NO production. Both nitrotyrosine fluorescence and NO levels were reduced in cells exposed to L-NNA or PTIO in the presence of Ab E22Q plus E 2 . Nitrotyrosine formation has been described in Alzheimer's disease brains (Castegna et al., 2003) . Therefore, we also evaluated nitrotyrosination in the frontal cortex vessels from Alzheimer's disease patients (Fig. 3E) . Immunohistochemical studies revealed the absence of either Ab vascular deposits or nitrotyrosination reactivity in sequential sections from controls without Alzheimer's disease (Fig. 3E, top panels) . In constrast, in brain sections from Alzheimer's disease patients, Ab vascular deposits correlating with protein nitrotyrosination were observed (Fig. 3E , bottom panels), suggesting that Ab-mediated vascular damage is associated to protein nitrotyrosination. No differences in the presence of nitrotyrosination associated to amyloid deposits were observed attending to the gender.
Identification of nitrotyrosinated proteins in HUVECs
In order to investigate the main target proteins for nitrotyrosination, we carried out a comparative 2D elecrophoretic analysis by western blot (Fig. 4) . While no nitrotyrosine immunoreactivity was detected in control HUVECs (Fig. 4A) , clear nitrotyrosination was present in HUVECs treated with Ab E22Q (Fig. 4B) , which was even more prominent in cells treated with Ab E22Q and E 2 (Fig. 4C) . The addition of L-NNA (Fig. 4D) or PTIO (Fig. 4E ) significantly reduced the nitrotyrosine immunoreactivity. The nitrotyrosinated proteins identified in the presence of Ab E22Q or Ab E22Q plus E 2 are listed in Table 1 .
Discussion
Oestrogens have been widely proposed as neuroprotective agents in a variety of in vivo and in vitro models (Behl, 2002; Mendelsohn, 2002a) . Moreover, clinical trials have associated E 2 with the retardation of the onset and progression of Alzheimer's disease (Tang et al., 1996; Kawas et al., 1997) , although other studies offered a less optimistic scenario (Grodstein et al., 2000; Rapp et al., 2003) . The putative neuroprotective effects of E 2 in Alzheimer's disease involve decreased Ab production, enhanced synthesis of cholineacetyltransferase, promotion of neuronal growth (GarciaSegura et al., 2001) , activation of potassium channels leading to vasodilatation (Valverde et al., 1999) and antioxidant properties (Moosmann and Behl, 1999) . The antioxidant effect of E 2 is independent of its interaction with ERs or other oestrogen-binding sites and is related to the phenolic OH group (Moosmann and Behl, 1999) , a chemical structure also present in a-tocopherol. Antioxidants inhibit membrane lipid peroxidation elicited by free radicals (Butterfield et al., 1999) as well as the intracellular damage triggered by Ab (Behl et al., 1994) .
Our study shows a cell type-dependent protective effect of oestrogen against Ab E22Q -mediated cytotoxicity. Oestrogen is Fig. 2 The role of ER on E 2 effect. HUVECs (A) and HA-VSMCs (B) were challenged with Ab E22Q fibrils and treated with E 2 in the presence of 0.1 mM ICI 182,780 and 0.1 mM tamoxifen. HUVECs were also challenged with Ab E22Q fibrils and 0.1 mM E 2 in the presence of 100 mM L-NNA and 10 mM PTIO (C). Data are mean 6 SEM values of four to nine experiments. *P < 0.05. A representative study on HUVECs was carried out with Ab E22Q fibrils and 1 mM 17a-oestradiol (D). Western blot analysis of phospho-Akt (Ser 473) expression was performed on HUVECs after 24 h with Ab E22Q fibrils and E 2 (E).
able to protect cortical neurons, glial cells and smooth muscle cells against Ab E22Q , but fails to protect ECs. Oestrogen uses both genomic and alternative (non-genomic) mechanisms of action that might implicate the known ER (ERa and ERb) (Nadal et al., 2001) or be ER-independent (e.g. its antioxidant effect) (Behl, 2002) . In the endothelium, eNOS produces NO by the conversion of L-arginine to L-citrulline (Radi, 2004) . eNOS is activated by E 2 via the ERa and PI3K/Akt pathway within caveoli signalling microdomains (Mendelsohn, 2002a) . HUVECs express ERa that colocalizes with caveolin-1 (data not shown). The lack of protection on endothelial cells is related to the E 2 -dependent activation of eNOS and the production of NO as inhibition of ER or eNOS enables the protective effect of E 2 . These results suggest that the protective role of E 2 is independent of its binding to the ER but related to its antioxidant properties. The fact that none of the cells treated with E 2 conferred protection against Ab E22Q at nanomolar concentrations is also suggestive of a mechanism of action different from its interaction with ERs. NO reacts with the superoxide anion producing highly reactive peroxynitrite (Radi, 2004) , which causes protein nitrotyrosination, a marker of cell damage reported in neurons and glial cells from Alzheimer's disease brains (Castegna et al., 2003) . We have found that vascular amyloid deposits correlate with nitrotyrosination in brain vessels from Alzheimer's disease patients. These findings are in agreement with previous studies describing endothelial cell degeneration in CAA (Miyakawa et al., 1997) and dysfunction of the Fig. 3 Production of NO and nitrotyrosination in HUVECs. Protein nitrotyrosination on HUVECs is indicated by green staining and nitrotyrosination intensity is shown using a pseudocolour scale (A). Protein nitrotryrosination on 1G11 ECs is indicated by green staining (B). Fluorescence intensity from HUVECs is represented as arbitrary units (NT; black bars) and NO production from HUVECs (NO; grey bars) is expressed as percentage of control cells (C). Data are mean 6 SEM values of seven to 10 separate experiments. *P < 0.05. Nitrotyrosination was also studied by using a NO donor (SNP) plus Ab E22Q fibrils on HUVECs (D). Colocalization of vascular amyloid deposits with nitrotyrosination (E) was performed in control and Alzheimer's disease patient brains. Representative pictures from female brain samples are shown.
blood-brain barrier (Wisniewski et al., 2000) . No difference in the level of nitrotyrosination associated to amyloid plaques was observed between samples from both genders. This fact may be explained based on the low levels of circulating oestrogens present in postmenopausal women (Orshal and Khahil, 2004) .
Ab fibrils act as a source of superoxide anion (Butterfield and Bush, 2004) , which can react with the basal levels of NO, owing to the high affinity of NO for the superoxide anion (Huie and Padmaja, 1993) , triggering nitrotyrosination. We have observed protein nitrotyrosination in HUVECs exposed to Ab E22Q alone. Higher levels of nitrotyrosination were observed in HUVECs exposed to Ab E22Q and E 2 , an effect reversed by PTIO and L-NNA. However, no increase in cell viability was seen in the presence of Ab E22Q and PTIO or L-NNA, suggesting that the main source of cell damage is provided by the Ab-induced oxidative stress, rather than nitrotyronization. Alternatively, it might be necessary to reach a nitrotyrosination threshold in order to produce cell death, as suggested previously (Paris et al., 1998) .
In this study, we have identified several proteins that are nitrotyrosinated under the conditions we have tested (Table 1) . They are functionally related to the regulation of energy production, cytoskeletal integrity, protein metabolism and protection against oxidative stress. The functions of these proteins should be inhibited since nitrotyrosination has been mainly associated with the loss of function and subsequent labelling for degradation via the proteasome (Grune et al., 1998) .
One of the most striking proteins to be nitrotyrosinated, TIM, is involved in the interconversion of dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-phosphate (GA3P) in the glycolytic pathway. If TIM function is altered, DHAP will be accumulated in the cell. Interestingly, inherited TIM deficiency leads to abnormal accumulation of DHAP and chronic neurodegeneration and has been also associated to degeneration of vascular endothelial cells (Ahmed et al., 2003) . It has also been proposed that a defective TIM could form pathological aggregates with microtubules (Orosz et al., 2000) .
Mitochondrial HSP75 plays an important role in preserving the integrity of mitochondria. This chaperone assists the folding of imported proteins to this organelle, as well as those proteins altered by oxidative stress. The inactivation of this enzyme is a key step in producing the mitochondrial impairment, failure of energetic metabolism and cerebral hypoperfusion (Aliev et al., 2003) .
The non-selenium GluPx (or 1-cys peroxiredoxin) is a cytosolic bifunctional enzyme with peroxidase and PLA 2 -like activities . It hydrolyses phospholipid hydroperoxides to free fatty acids hydroperoxides, playing an important role in preserving the membrane function and integrity (Fisher et al., 1999) . Its nitrotyrosination could produce an increase in the oxidative injury.
TCP-1 is a cytosolic chaperone that assists in the folding of tubulin, actin and vinculin. The abnormal folding of cytoskeletal proteins in endothelial cells might determine alterations in cell adhesion, loss of the blood-brain barrier selectivity and endothelial apoptosis (Li et al., 1999) .
Eukaryotic translation elongation factor 2 (ef-2) is responsible for the elongation phase during protein synthesis. It has been reported that oxidative stress reduces protein synthesis (Patel et al., 2002) , thereby nitrotyrosination of ef-2 might result in reduced protein synthesis.
Finally, 26S proteasome is one of the main degradation systems inside the cell (Goldberg, 2003) . The nitrotyrosination of 26S proteasome could alter the degradation of proteins in a critical situation as oxidative stress.
In conclusion, our study shows that the beneficial effect of E 2 against Ab-mediated cell damage in endothelial cells is ERindependent, while its endothelial harmful effect is through its interaction with ER, via NO production and protein nitrotyrosination. Although there is not increased cell death in the presence of Ab E22Q and E 2 compared with Ab E22Q alone, there Fig. 4 Identification of nitrotyrosinated proteins. Western blots show nitrotyrosinated proteins from HUVECs (A) challenged with Ab E22Q (B) and 10 mM E 2 (C) in the presence of 100 mM L-NNA (D) and 10 mM PTIO (E). The proteins identified to be nitrotyrosinated were triose phosphate isomerase (1), peroxiredoxin 6 (2), 26S proteasome (3), T-complex protein (4), MTHSP75 (5), Metavinculin (6) and eukaryotic translation elongation factor 2 (7).
is a significant increase of nitrotyrosination in enzymes involved in glucose metabolism, energetic balance, repairing systems, protein degradation and cytoskeleton, which most likely compromise cell functions.
Oestrogen effects are complex, with many preliminary studies praising its neuro-and vascular-protective effects (Behl, 2002; Mendelsohn, 2002a) , whereas clinical trial have yielded disappointing results (Grodstein et al., 2000; Viscoli et al., 2001; Hippisley-Cox et al., 2003; Rapp et al., 2003) . Our data suggest possible damaging effects of E 2 in vascular disorders dealing with oxidative stress conditions, such as cerebral amyloid angiopathy (Muñoz et al., 2002) , stroke and ischaemia-reperfusion conditions (Gilgun-Sherki et al., 2002) , where an overproduction of NO can be harmful (Hobbs et al., 1999) . They might also cast light on the mechanisms that will explain recently reported worsening of the injury caused by recurrent cerebral ischaemia in women undergoing hormone replacement therapy (Viscoli et al., 2001; Rossouw et al., 2002) .
